Phase III study of F901318 for invasive aspergillosis
Phase of Trial: Phase III
Latest Information Update: 11 Jul 2016
At a glance
- Drugs F 901318 (Primary)
- Indications Aspergillosis
- Focus Registrational; Therapeutic Use
- Sponsors F2G
- 11 Jul 2016 According to an F2G media release, the company plans to initiate this trial in 1H 2017.
- 24 Jun 2016 New trial record
- 20 Jun 2016 According to F2G media release, thae company plans to initiate this trial in the second half of 2016.